Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Majority of sinus infections are reported to be caused by common cold and viral infections. These infections are classified as chronic and acute based on severity.
The chronic ones are those lasting for more than 3 months. Acute sinusitis get cured within 30 days.
At preliminary stage, sinus infections get diagnosed by physically inspecting characteristics of nasal mucosa, nasal septum’s structure, and presence of polyps.
At times, even imaging procedures like MRI (Magnetic Resonance Imaging), ultrasound, and CT (computed tomography) could be used to gauge the severity.
The commonly prescribed sinus therapeutic drugs include painkillers, corticosteroids, sulfonamides, antibiotics, and antihistamines.
The antibiotics used for treating bacterial infections herein include cephalospotin’s, penicillin, and macrolides.
Prednisone, triamcinolone, fluticasone, and mometastone are amongst the corticosteroids used to treat sinus infections. Sulfa drugs are inclusive of trimethoprim and sulfamethoxazole.
Antibiotics are expected to witness exponentiation in the forecast period. This could be attributed to diagnostic technologies being developed post introducing rapid microbial tests.
Besides, market players are looking for expansion in the markets of Asia-Pacific like Indonesia, Philippines, China, and India. This trend is expected to boost the market during the forecast period.
The other treatment options include bacterial lysates, capsaicin, anti-IL5, anti-IgE, and antifungals
The sinus therapeutic drugs market players are treading the innovative path followed by approvals to table their superiority. These measures are bound to give impetus to the market during the forecast period.
For instance –
Principal Consultant
The ongoing pandemic has compelled the sinus therapeutic drugs market players to speed up the production of drugs to address it, as it is a known fact that disorders in respiratory track can increase the risk of contraction.
For instance –
Since the last few months, Aviptaadil Covid-19 therapeutic has been treating critical Covid-19.
Traditionally, the US and Western European countries have remained the most lucrative markets for sinus therapeutic drug manufacturers. The scenario is likely to witness significant change during the forecast period, as many countries in Asia Pacific are offering lucrative opportunities.
The Asia Pacific sinus therapeutics drugs market is likely to grow at the fastest pace in the forecast period, as the players are expanding in this region, and some of them are also reported to shift their base over here.
Moreover, many countries in Asia Pacific have world’s worst air quality, and respiratory disorders have witnessed a rapid spike, with rise in industrialization.
The market players are launching new products to stand out as differentiators. This strategy is being emphasized on, and has kept the users guessing, regarding novelty.
For instance –
The major players in the sinus therapeutic drug market include:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global sinus therapeutic drugs market is expected to witness a substantial CAGR of over 4% between 2022 and 2032. The onslaught of Covid-19 has resulted in increase in production of these drugs as it is directly related to disorders in the nasal tract.
The market players, though vying for innovation, should also think more from the inorganic growth perspective. As such, they should be looking forward to go for mergers, acquisitions, partnerships, joint ventures to be able to reach out to a broader audience.
Route of Administration
Distribution Channel
Disease Type
Geography
The sinus therapeutic drugs market is likely to secure a CAGR of 4% through 2032.
The sinus therapeutic drugs market size is estimated to cross US$ 6.35 Bn by 2032.
The sinus therapeutic drugs market is likely to record a value of US$ 4.29 Bn in 2022.
US is likely to lead the sinus therapeutic drugs market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Drug Development Trends
4. Key Success Factors
4.1. Adoption Analysis of Sinus Therapeutic Drugs
4.2. Regulatory Scenario
4.3. Reimbursement Scenario
4.4. Pipeline Analysis
4.5. Key Promotional Strategies, By Manufacturers
5. Sinus Therapeutic Drug Market Demand (Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030
5.1. Historical Market Value (US$ Mn) Analysis, 2015-2019
5.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Background
6.1. Macro-Economic Factors
6.1.1. Global GDP Growth Outlook
6.1.2. Per Capita Healthcare Expenditure Outlook
6.2. Forecast Factors - Relevance & Impact
6.2.1. Growing Prevalence of Severe Allergic Asthma
6.2.2. Cost of Sinus Therapeutic Drug
6.2.3. Consolidation of Healthcare Industry
6.2.4. Increase in Patient Pool
6.3. Value Chain
6.4. Market Dynamics
6.4.1. Drivers
6.4.2. Restraints
6.4.3. Opportunity Analysis
6.5. COVID19 Crisis Analysis
6.5.1. Current COVID19 Statistics and Probable Future Impact
6.5.2. Current GDP Projection and Probable Impact
6.5.3. Current Economic Projection as compared to 2008 Economic analysis
6.5.4. COVID19 and Impact Analysis
6.5.4.1. Revenue By Drug Class
6.5.4.2. Revenue By Disease Type
6.5.4.3. Revenue By Route of Administration
6.5.4.4. Revenue By Distribution Channel
6.5.4.5. Revenue By Country
6.5.5. 2020 Market Scenario
6.5.6. Quarter by Quarter Forecast
6.5.7. Projected recovery Quarter
6.5.8. Recovery Scenario – Short term, Midterm and Long Term Impact
7. Global Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Class
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) By Drug Class, 2015-2019
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2020-2030
7.3.1. Аntіhіѕtаmіnеѕ
7.3.2. Аnаlgеѕісѕ
7.3.3. Ѕulрhоnаmіdеѕ
7.3.4. Соrtісоѕtеrоіdѕ
7.3.5. Аntіbіоtісѕ
7.3.6. NSAID’s
7.3.7. Оthеr Drug Сlаѕѕеѕ
7.4. Market Attractiveness Analysis By Drug Class
8. Global Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030, by Disease Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) By Disease Type, 2015-2019
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2020-2030
8.3.1. Асutе Sіnuѕіtіѕ
8.3.2. Ѕub-асutе Sіnuѕіtіѕ
8.3.3. Сhrоnіс Sіnuѕіtіѕ
8.4. Market Attractiveness Analysis By Disease Type
9. Global Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030, by Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2019
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2020-2030
9.3.1. Oral
9.3.2. Topical
9.3.3. Injectable
9.4. Market Attractiveness Analysis By Route of Administration
10. Global Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015-2019
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020-2030
10.3.1. Ноѕріtаl Рhаrmасіеѕ
10.3.2. Rеtаіl Рhаrmасіе
10.3.3. Оnlіnе Рhаrmасіеѕ
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 - 2018
11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 - 2029
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Drug Class
12.3.3. By Disease Type
12.3.4. By Route of Administration
12.3.5. By Distribution Channel
12.4. Market Attractiveness Analysis
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. Latin America Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014 - 2018
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Drug Class
13.3.3. By Disease Type
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. Europe Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy2020-2030
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Drug Class
14.3.3. By Disease Type
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. South Asia Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy2020-2030
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Indonesia
15.3.1.4. Malaysia
15.3.1.5. Rest of South Asia
15.3.2. By Drug Class
15.3.3. By Disease Type
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. East Asia Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Drug Class
16.3.3. By Disease Type
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. Oceania Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Drug Class
17.3.3. By Disease Type
17.3.4. By Route of Administration
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. Middle East and Africa Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Turkey
18.3.1.3. South Africa
18.3.1.4. Rest of Middle East and Africa
18.3.2. By Drug Class
18.3.3. By Disease Type
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
19. Key and Emerging Countries Sinus Therapeutic Drug Market Analysis 2015-2019 and Forecast 2020-2030
19.1. Introduction
19.1.1. Market Value Proportion Analysis, By Key Countries
19.1.2. Global Vs. Country Growth Comparison
19.2. U.S. Sinus Therapeutic Drug Market Analysis
19.2.1. By Drug Class
19.2.2. By Disease Type
19.2.3. By Route of Administration
19.2.4. By Distribution Channel
19.3. Canada Sinus Therapeutic Drug Market Analysis
19.3.1. By Drug Class
19.3.2. By Disease Type
19.3.3. By Route of Administration
19.3.4. By Distribution Channel
19.4. Mexico Sinus Therapeutic Drug Market Analysis
19.4.1. By Drug Class
19.4.2. By Disease Type
19.4.3. By Route of Administration
19.4.4. By Distribution Channel
19.5. Brazil Sinus Therapeutic Drug Market Analysis
19.5.1. By Drug Class
19.5.2. By Disease Type
19.5.3. By Route of Administration
19.5.4. By Distribution Channel
19.6. U.K. Sinus Therapeutic Drug Market Analysis
19.6.1. By Drug Class
19.6.2. By Disease Type
19.6.3. By Route of Administration
19.6.4. By Distribution Channel
19.7. Germany Sinus Therapeutic Drug Market Analysis
19.7.1. By Drug Class
19.7.2. By Disease Type
19.7.3. By Route of Administration
19.7.4. By Distribution Channel
19.8. France Sinus Therapeutic Drug Market Analysis
19.8.1. By Drug Class
19.8.2. By Disease Type
19.8.3. By Route of Administration
19.8.4. By Distribution Channel
19.9. Italy Sinus Therapeutic Drug Market Analysis
19.9.1. By Drug Class
19.9.2. By Disease Type
19.9.3. By Route of Administration
19.9.4. By Distribution Channel
19.10. Spain Sinus Therapeutic Drug Market Analysis
19.10.1. By Drug Class
19.10.2. By Disease Type
19.10.3. By Route of Administration
19.10.4. By Distribution Channel
19.11. BENELUX Sinus Therapeutic Drug Market Analysis
19.11.1. By Drug Class
19.11.2. By Disease Type
19.11.3. By Route of Administration
19.11.4. By Distribution Channel
19.12. Russia Sinus Therapeutic Drug Market Analysis
19.12.1. By Drug Class
19.12.2. By Disease Type
19.12.3. By Route of Administration
19.12.4. By Distribution Channel
19.13. China Sinus Therapeutic Drug Market Analysis
19.13.1. By Drug Class
19.13.2. By Disease Type
19.13.3. By Route of Administration
19.13.4. By Distribution Channel
19.14. Japan Sinus Therapeutic Drug Market Analysis
19.14.1. By Drug Class
19.14.2. By Disease Type
19.14.3. By Route of Administration
19.14.4. By Distribution Channel
19.15. South Korea Sinus Therapeutic Drug Market Analysis
19.15.1. By Drug Class
19.15.2. By Disease Type
19.15.3. By Route of Administration
19.15.4. By Distribution Channel
19.16. India Sinus Therapeutic Drug Market Analysis
19.16.1. By Drug Class
19.16.2. By Disease Type
19.16.3. By Route of Administration
19.16.4. By Distribution Channel
19.17. Australia Sinus Therapeutic Drug Market Analysis
19.17.1. By Drug Class
19.17.2. By Disease Type
19.17.3. By Route of Administration
19.17.4. By Distribution Channel
19.18. New Zealand Sinus Therapeutic Drug Market Analysis
19.18.1. By Drug Class
19.18.2. By Disease Type
19.18.3. By Route of Administration
19.18.4. By Distribution Channel
19.19. GCC Countries Sinus Therapeutic Drug Market Analysis
19.19.1. By Drug Class
19.19.2. By Disease Type
19.19.3. By Route of Administration
19.19.4. By Distribution Channel
19.20. Turkey Sinus Therapeutic Drug Market Analysis
19.20.1. By Drug Class
19.20.2. By Disease Type
19.20.3. By Route of Administration
19.20.4. By Distribution Channel
19.21. South Africa Sinus Therapeutic Drug Market Analysis
19.21.1. By Drug Class
19.21.2. By Disease Type
19.21.3. By Route of Administration
19.21.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Concentration
20.3. Market Share Analysis of Top Players
20.4. Market Presence Analysis
20.4.1. By Regional footprint of Players
20.4.2. Product foot print by Players
20.4.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. AstraZeneca
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
21.3.1.4. Sales Footprint
21.3.1.5. Strategy Overview
21.3.1.5.1. Marketing Strategy
21.3.1.5.2. Product Strategy
21.3.1.5.3. Channel Strategy
21.3.2. Bausch Health
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
21.3.2.4. Sales Footprint
21.3.2.5. Strategy Overview
21.3.2.5.1. Marketing Strategy
21.3.2.5.2. Product Strategy
21.3.2.5.3. Channel Strategy
21.3.3. Nоvаrtіѕ АG
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
21.3.3.4. Sales Footprint
21.3.3.5. Strategy Overview
21.3.3.5.1. Marketing Strategy
21.3.3.5.2. Product Strategy
21.3.3.5.3. Channel Strategy
21.3.4. Ѕun Рhаrmасеutісаl Іnduѕtrіеѕ, Іnс
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
21.3.4.4. Sales Footprint
21.3.4.5. Strategy Overview
21.3.4.5.1. Marketing Strategy
21.3.4.5.2. Product Strategy
21.3.4.5.3. Channel Strategy
21.3.5. Rеddу'ѕ Lаbоrаtоrіеѕ, Іnс.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
21.3.5.4. Sales Footprint
21.3.5.5. Strategy Overview
21.3.5.5.1. Marketing Strategy
21.3.5.5.2. Product Strategy
21.3.5.5.3. Channel Strategy
21.3.6. Теа Рhаrmасеutісаl Іnduѕtrіеѕ Ltd.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
21.3.6.4. Sales Footprint
21.3.6.5. Strategy Overview
21.3.6.5.1. Marketing Strategy
21.3.6.5.2. Product Strategy
21.3.6.5.3. Channel Strategy
21.3.7. Frеѕеnіuѕ Каbі UЅА
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
21.3.7.4. Sales Footprint
21.3.7.5. Strategy Overview
21.3.7.5.1. Marketing Strategy
21.3.7.5.2. Product Strategy
21.3.7.5.3. Channel Strategy
21.3.8. Јоhnѕоn & Јоhnѕоn
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
21.3.8.4. Sales Footprint
21.3.8.5. Strategy Overview
21.3.8.5.1. Marketing Strategy
21.3.8.5.2. Product Strategy
21.3.8.5.3. Channel Strategy
21.3.9. Рfіzеr Іnс
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
21.3.9.4. Sales Footprint
21.3.9.5. Strategy Overview
21.3.9.5.1. Marketing Strategy
21.3.9.5.2. Product Strategy
21.3.9.5.3. Channel Strategy
21.3.10. Јаnѕѕеn Рhаrmасеutісаlѕ, Іnс.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
21.3.10.4. Sales Footprint
21.3.10.5. Strategy Overview
21.3.10.5.1. Marketing Strategy
21.3.10.5.2. Product Strategy
21.3.10.5.3. Channel Strategy
21.3.11. GlaxoSmithKline plc
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Profitability by Market Segments (Product/Channel/Region)
21.3.11.4. Sales Footprint
21.3.11.5. Strategy Overview
21.3.11.5.1. Marketing Strategy
21.3.11.5.2. Product Strategy
21.3.11.5.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Sinus Therapeutic Drugs Market
